Literature DB >> 29088342

Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.

Xavier Roblin1, Stéphane Paul1, Shomron Ben-Horin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29088342     DOI： 10.1093/ecco-jcc/jjx142

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


× No keyword cloud information.
  5 in total

1.  Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.

Authors:  Claire Liefferinckx; Bram Verstockt; Ann Gils; Sophie Tops; Wouter Van Moerkercke; Severine Vermeire; Denis Franchimont
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

2.  Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics.

Authors:  Eric J Mao; Sara Lewin; Jonathan P Terdiman; Kendall Beck
Journal:  BMJ Open Gastroenterol       Date:  2018-11-09

Review 3.  Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.

Authors:  Anand Kumar; Dana Lukin; Robert Battat; Monica Schwartzman; Lisa A Mandl; Ellen Scherl; Randy S Longman
Journal:  J Gastroenterol       Date:  2020-05-04       Impact factor: 7.527

Review 4.  Inflammatory Bowel Disease-related Spondyloarthritis: The Last Unexplored Territory of Rheumatology.

Authors:  Nikoleta Zioga; Dionysios Kogias; Vasiliki Lampropoulou; Nikolaos Kafalis; Charalampos Papagoras
Journal:  Mediterr J Rheumatol       Date:  2022-04-15

Review 5.  Combination of Biological Agents in Moderate to Severe Pediatric Inflammatory Bowel Disease: A Case Series and Review of the Literature.

Authors:  Christine Olbjørn; Jon Bergreen Rove; Jørgen Jahnsen
Journal:  Paediatr Drugs       Date:  2020-08       Impact factor: 3.022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.